Bone-Muscle Crosstalk: Musculoskeletal Complications of Chemotherapy

Brian A. Hain, David L. Waning

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Purpose of Review: Chemotherapy drugs combat tumor cells and reduce metastasis. However, a significant side effect of some chemotherapy strategies is loss of skeletal muscle and bone. In cancer patients, maintenance of lean tissue is a positive prognostic indicator of outcomes and helps to minimize the toxicity associated with chemotherapy. Bone-muscle crosstalk plays an important role in the function of the musculoskeletal system and this review will focus on recent findings in preclinical and clinical studies that shed light on chemotherapy-induced bone-muscle crosstalk. Recent Findings: Chemotherapy-induced loss of bone and skeletal muscle are important clinical problems. Bone antiresorptive drugs prevent skeletal muscle weakness in preclinical models. Chemotherapy-induced loss of bone can cause muscle weakness through both changes in endocrine signaling and mechanical loading between muscle and bone. Summary: Chemotherapy-induced changes to bone-muscle crosstalk have implications for treatment strategies and patient quality of life. Recent findings have begun to determine the role of chemotherapy in bone-muscle crosstalk and this review summarizes the most relevant clinical and preclinical studies.

Original languageEnglish (US)
Pages (from-to)433-441
Number of pages9
JournalCurrent Osteoporosis Reports
Issue number6
StatePublished - Dec 2022

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Bone-Muscle Crosstalk: Musculoskeletal Complications of Chemotherapy'. Together they form a unique fingerprint.

Cite this